Hospital
Tishomingo Health Services, INC.
Tishomingo Health Services, INC. was paid $4.10M by Medicaid between Jan 2018 and Dec 2024, across 83 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoTISHOMINGO HEALTH SERVICES, INC.
IUKA, MS 38852
IUKA, MS 38852
33aNPI1548376700assigned 08/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.10M
24GClaims103,725
24DCodes billed83
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#44 of 77
Median peer was paid$8.23M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,584 | $640K | |
| 2019 | 13,397 | $571K | |
| 2020 | 9,223 | $362K | |
| 2021 | 12,205 | $530K | |
| 2022 | 15,127 | $631K | |
| 2023 | 18,867 | $682K | |
| 2024incomplete | 18,322 | $680K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 8,516 | 7,034 | $1.11M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 4,630 | 3,938 | $768K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.5% | 6,059 | 5,315 | $309K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.9% | 1,234 | 1,043 | $202K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.2% | 1,751 | 1,581 | $174K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.0% | 4,176 | 3,525 | $163K |
| 87428 | 3.9% | 2,744 | 2,338 | $160K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 830 | 733 | $150K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.7% | 2,581 | 524 | $112K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 1,743 | 1,561 | $92K |
| 71045 | Radiologic examination, chest; single view | 2.2% | 2,663 | 2,370 | $92K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 1,465 | 1,044 | $82K |
71 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.7% | 2,414 | $68K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.6% | 5,028 | $65K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 598 | $53K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 2,452 | $46K |
| 80053 | Comprehensive metabolic panel | 1.1% | 6,817 | $44K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 8,331 | $41K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 932 | $38K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,405 | $35K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 218 | $29K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 404 | $28K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,040 | $25K |
| 87400 | <1% | 1,859 | $23K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 96 | $22K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,628 | $14K |
| 83880 | <1% | 866 | $12K | |
| 87807 | <1% | 1,002 | $11K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 87 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,878 | $11K |
| 74018 | <1% | 233 | $11K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 963 | $10K |
| G0378 | Hospital observation service, per hour | <1% | 59 | $10K |
| 84484 | <1% | 1,779 | $10K | |
| 81001 | <1% | 4,138 | $9K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 432 | $8K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 94 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 870 | $6K |
| 86140 | <1% | 979 | $3K | |
| 83735 | <1% | 709 | $3K | |
| 80061 | Lipid panel | <1% | 338 | $3K |
| 83690 | <1% | 590 | $3K | |
| 82728 | <1% | 241 | $2K | |
| 87186 | <1% | 415 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,774 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 33 | $2K |
| 81025 | <1% | 302 | $2K | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 155 | $1K |
| 82607 | <1% | 131 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 82 | $1K |
| 73030 | <1% | 25 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 156 | $997.71 |
| 84439 | <1% | 180 | $938.76 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $799.58 |
| 83605 | <1% | 167 | $593.26 | |
| Q3014 | Telehealth originating site facility fee | <1% | 34 | $466.36 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 474 | $424.20 |
| 81003 | <1% | 75 | $419.49 | |
| 82150 | <1% | 66 | $389.21 | |
| 82043 | <1% | 102 | $363.58 | |
| 83540 | <1% | 74 | $333.54 | |
| 82570 | <1% | 104 | $331.07 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $292.89 |
| 80305 | <1% | 29 | $251.88 | |
| 83550 | <1% | 45 | $243.83 | |
| 87040 | <1% | 58 | $186.52 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,376 | $178.15 |
| 82553 | <1% | 14 | $139.45 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 114 | $123.20 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 847 | $54.22 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 459 | $22.40 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,234 | $15.89 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 62 | $0.67 |
| A9270 | Non-covered item or service | 0% | 1,151 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 277 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 32 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 15 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 12 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 485 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 175 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 62 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 16 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREPPERT, JOSEPH (CFO)
Parent organizationTISHOMINGO HEALTH SERVICES, INC.
| Provider | Location | Paid |
|---|---|---|
| North Mississippi Medical Center, INC. | Tupelo, MS | $1.56M |
| Marion Regional Medical Center, INC. | Hamilton, AL | $920K |
| North Mississippi Medical Center, INC. | Tupelo, MS | $200K |
| Tishomingo Health Services, INC. | Iuka, MS | $67K |
| North Mississippi Medical Center, INC. | Oxford, MS | $12K |
| North Mississippi Medical Center, INC. | Starkville, MS | $7K |
| North Mississippi Medical Center, INC. | Tupelo, MS | $741.99 |
| Webster Health Services INC | Eupora, MS | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.